PRN: Elsevier Announces Publishing The Ocular Surface

19/gen/2012 14.43.18 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Elsevier Announces Publishing The Ocular Surface

 
[19-January-2012]
 

NEW YORK, January 19, 2012 /PRNewswire/ --

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce newly acquiring The Ocular Surface, a peer-reviewed journal focusing on the external eye and vision. As per January 2012 Elsevier will continue the publication of the quarterly journal.


The Ocular Surface delivers reviews of important work in laboratory science, clinical science, and clinical practice related to the external eye and vision, along with coverage of ongoing studies, patents pending, conference highlights, and more. The Ocular Surface has an Impact Factor of 3.103 and is ranked 7th out of 56 journals in the Ophthalmology category according to the 2011 Journal Citation Reports© published by Thomson Reuters. The journal has remained in the top 10 ranking of Impact Factors for the last three years.


Gary N. Foulks, MD, Editor-in-Chief of The Ocular Surface, said of the acquisition: "We are very pleased to start working with Elsevier. Together we will bring The Ocular Surface to a new level of excellence in serving our professional community."


"Elsevier is truly honored to publish The Ocular Surface. This premier journal represents innovative, high-quality content, and is an excellent addition to our leading ophthalmology journals program," Nancy Axelrod, Executive Publisher at Elsevier added. 

 

About The Ocular Surface


The Ocular Surface, a quarterly, a peer-reviewed journal, is an authoritative resource that integrates and interprets major findings in diverse fields related to the ocular surface, including ophthalmology, optometry, genetics, molecular biology, pharmacology, immunology, infectious disease, and epidemiology. Its critical review articles cover the most current knowledge on medical and surgical management of ocular surface pathology, new understandings of ocular surface physiology, the meaning of recent discoveries on how the ocular surface responds to injury and disease, and updates on drug and device development.

About Elsevier


Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institu! tions deliver better outcomes more cost-effectively.


A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact    
Rachael Zaleski
Elsevier
+1-215-239-3658
rachael.zaleski@elsevier.com



Company Codes: LSE:REL, NYSE:RUK, NYSE:ENL
blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl